贝那利珠单抗治疗OCS依赖性重症哮喘的疗效：真实世界研究2年治疗的效果
2023/02/20
摘要
背景：罹患口服糖皮质激素（OCS）依赖性重症哮喘的患者可被视为哮喘患者的一个亚组，病情较重，发生并发症的风险高，且与长期应用OCS相关。生物药物的引入代表了重症哮喘治疗策略的一个转折点，为OCS提供了有效的替代方案。与其他抗IL-5药物一样，贝那利珠单抗已被证明可以减少病情加重和OCS摄入量/剂量，并改善症状控制和肺功能。虽然这些发现在现实生活中也得到了证实，但关于长期疗效的数据仍然有限。
方法：本项回顾性研究通过分析临床、生物学和功能数据，评估了贝那利珠单抗治疗44例OCS依赖性重度哮喘患者2年的效果。
结果：使用贝那利珠单抗治疗2年后，59.4%的患者停用OCS，继续使用OCS的患者平均剂量比基线减少了约85%。同时，85%的患者哮喘得到了很好的控制（ACT评分>20）且没有恶化，41.6%的患者肺功能正常。
结论：本研究结果支持了在现实生活中，贝那利珠单抗治疗OCS依赖性重症哮喘的长期有效性，这表明其可能降低成本和不良药物事件等并发症。
Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting.
Vitale C, Maglio A, Pelaia C, D'Amato M, Ciampo L, Pelaia G, Molino A, Vatrella A.
Abstract
BACKGROUND:Patients with severe OCS-dependent asthma can be considered a subgroup of asthma patients with severe disease and great risk of complications, related to chronic OCS use. The introduction of biological drugs has represented a turning point in the therapeutic strategy for severe asthma, offering a valid alternative to OCS. Benralizumab, like other anti-IL-5 agents, has been shown to reduce exacerbations and OCS intake/dosage and improve symptom control and lung function. While these findings have also been confirmed in real-life studies, data on long-term efficacy are still limited.
METHODS:In this retrospective study, we evaluated the effects of 2 years of treatment with benralizumab on 44 patients with OCS-dependent severe asthma by analyzing clinical, biological and functional data.
RESULTS:After 2 years of benralizumab, 59.4% discontinued OCS and patients who continued to use OCS had their mean dose reduced by approximately 85% from baseline. Meanwhile, 85% of patients had their asthma well-controlled (ACT score > 20) and had no exacerbations, and 41.6% had normal lung function.
CONCLUSIONS:Our findings support the long-term effectiveness of benralizumab in severe OCS-dependent asthma in a real-life setting, suggesting potential reductive effects on costs and complications such as adverse pharmacological events.
背景：罹患口服糖皮质激素（OCS）依赖性重症哮喘的患者可被视为哮喘患者的一个亚组，病情较重，发生并发症的风险高，且与长期应用OCS相关。生物药物的引入代表了重症哮喘治疗策略的一个转折点，为OCS提供了有效的替代方案。与其他抗IL-5药物一样，贝那利珠单抗已被证明可以减少病情加重和OCS摄入量/剂量，并改善症状控制和肺功能。虽然这些发现在现实生活中也得到了证实，但关于长期疗效的数据仍然有限。
方法：本项回顾性研究通过分析临床、生物学和功能数据，评估了贝那利珠单抗治疗44例OCS依赖性重度哮喘患者2年的效果。
结果：使用贝那利珠单抗治疗2年后，59.4%的患者停用OCS，继续使用OCS的患者平均剂量比基线减少了约85%。同时，85%的患者哮喘得到了很好的控制（ACT评分>20）且没有恶化，41.6%的患者肺功能正常。
结论：本研究结果支持了在现实生活中，贝那利珠单抗治疗OCS依赖性重症哮喘的长期有效性，这表明其可能降低成本和不良药物事件等并发症。
(中日友好医院呼吸与危重症医学科 张婧媛 摘译 林江涛 审校)
(J Clin Med. 2023 Jan 27;12(3):985. doi: 10.3390/jcm12030985.)
(J Clin Med. 2023 Jan 27;12(3):985. doi: 10.3390/jcm12030985.)
Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting.
Vitale C, Maglio A, Pelaia C, D'Amato M, Ciampo L, Pelaia G, Molino A, Vatrella A.
Abstract
BACKGROUND:Patients with severe OCS-dependent asthma can be considered a subgroup of asthma patients with severe disease and great risk of complications, related to chronic OCS use. The introduction of biological drugs has represented a turning point in the therapeutic strategy for severe asthma, offering a valid alternative to OCS. Benralizumab, like other anti-IL-5 agents, has been shown to reduce exacerbations and OCS intake/dosage and improve symptom control and lung function. While these findings have also been confirmed in real-life studies, data on long-term efficacy are still limited.
METHODS:In this retrospective study, we evaluated the effects of 2 years of treatment with benralizumab on 44 patients with OCS-dependent severe asthma by analyzing clinical, biological and functional data.
RESULTS:After 2 years of benralizumab, 59.4% discontinued OCS and patients who continued to use OCS had their mean dose reduced by approximately 85% from baseline. Meanwhile, 85% of patients had their asthma well-controlled (ACT score > 20) and had no exacerbations, and 41.6% had normal lung function.
CONCLUSIONS:Our findings support the long-term effectiveness of benralizumab in severe OCS-dependent asthma in a real-life setting, suggesting potential reductive effects on costs and complications such as adverse pharmacological events.
上一篇：
tezepelumab与mepolizumab,benralizumab和dupilumab治疗嗜酸性哮喘的疗效比较:贝
下一篇：
生物制剂在SARS-CoV-2感染严重哮喘患者中的安全性研究:一项前瞻性研究
